Verrica Pharmaceuticals Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $5.0M | $5.1M | $14.3M | $12.7M | $3.4M | $344.0K | $-1.8M |
| Cost of Revenue | — | — | — | — | — | $700.0K | $800.0K | $400.0K |
| Gross Profit | — | — | — | — | — | $2.7M | $-456.0K | $-2.2M |
| Gross Margin | — | — | — | — | — | 79.6% | -132.6% | 122.5% |
| Operating Expenses | ||||||||
| Research & Development | $6.0M | $3.9M | $2.5M | $2.2M | $1.8M | $2.3M | $1.2M | $2.4M |
| SG&A Expense | $10.3M | $10.0M | $8.1M | $9.4M | $8.9M | $8.8M | $9.9M | $16.1M |
| Operating Income | $-13.1M | $-9.7M | $-7.2M | $1.6M | $1.5M | $-8.1M | $-11.4M | $-20.7M |
| Operating Margin | -223.4% | -193.4% | -141.2% | 11.3% | 11.9% | -236.4% | -3,316.9% | 1,162.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-13.2M | $-9.7M | $-8.1M | $-274.0K | $204.0K | $-9.7M | $-16.2M | $-22.9M |
| Net Margin | -224.4% | -192.8% | -158.6% | -1.9% | 1.6% | -283.3% | -4,709.9% | 1,283.5% |
| EPS (Basic) | $-0.62 | $-0.45 | $-0.64 | $-0.02 | $0.01 | $-0.52 | $-2.88 | $-2.44 |
| EPS (Diluted) | $-0.62 | $-0.45 | $-0.64 | $-0.02 | $0.01 | $-0.52 | $-2.88 | $-2.44 |
| Shares Outstanding (Basic) | 21.3M | 21.3M | 10.7M | 19.0M | 19.0M | 19.0M | 10.4M | 9.4M |
| Shares Outstanding (Diluted) | 21.3M | 21.3M | 10.7M | 19.0M | 19.0M | 19.0M | 10.4M | 9.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |